PMID- 16002160
OWN - NLM
STAT- MEDLINE
DCOM- 20060927
LR  - 20181201
IS  - 0167-5273 (Print)
IS  - 0167-5273 (Linking)
VI  - 109
IP  - 1
DP  - 2006 Apr 28
TI  - The impact of early administration of low-dose atorvastatin treatment on 
      inflammatory process, in patients with unstable angina and low cholesterol level.
PG  - 48-52
AB  - BACKGROUND: Lipid-lowering agents are known to reduce long-term mortality in 
      patients with stable angina or multiple risk factors. However, the effects of 
      lipid-lowering treatment on inflammatory process during and immediately after the 
      acute phase of unstable angina remain unclear. In this study we assessed the 
      effects of low-dose atorvastatin treatment, on inflammatory process in patients 
      admitted for unstable angina with low cholesterol level. METHODS: Forty-seven 
      normocholesterolemic patients with unstable angina were randomized into two 
      groups, and received atorvastatin 10 mg/day (n = 24) or no statin (n = 23) for 6 
      weeks. Circulating levels of inteleukin 6 (IL-6), monocyte chemoattractant 
      protein-1 (MCP-1), tumor necrosis factor alpha (TNF-alpha) and soluble vascular 
      cell adhesion molecule (sVCAM-1) were measured by their admission, and at the 1st 
      and 6th week of the study. RESULTS: Serum levels of MCP-1 and sVCAM-1 were 
      significantly increased in the control group (p < 0.05) while remained unaffected 
      in the atorvastatin-treated group six weeks after admission. However, IL-6 and 
      TNF-alpha levels were similarly decreased in both atorvastatin-treated and 
      control groups. CONCLUSION: Low-dose atorvastatin treatment modifies inflammatory 
      process in patients with unstable angina and low cholesterol level, an effect 
      seen at 6 weeks but not 1 week after admission.
FAU - Tousoulis, Dimitris
AU  - Tousoulis D
AD  - Cardiology Unit, Hippokration Hospital, Athens University Medical School, 69 S. 
      Karagiorga, 16675, Glifada, Athens, Greece. tousouli@med.uoa.gr
FAU - Antoniades, Charalambos
AU  - Antoniades C
FAU - Katsi, Vasiliki
AU  - Katsi V
FAU - Bosinakou, Erini
AU  - Bosinakou E
FAU - Kotsopoulou, Maria
AU  - Kotsopoulou M
FAU - Tsioufis, Costas
AU  - Tsioufis C
FAU - Stefanadis, Christodoulos
AU  - Stefanadis C
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20050706
PL  - Netherlands
TA  - Int J Cardiol
JT  - International journal of cardiology
JID - 8200291
RN  - 0 (Anticholesteremic Agents)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Interleukin-6)
RN  - 0 (Pyrroles)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Angina, Unstable/blood/*drug therapy/physiopathology
MH  - Anticholesteremic Agents/*administration & dosage
MH  - Atorvastatin
MH  - Chemokine CCL2/blood
MH  - Cholesterol/blood
MH  - Female
MH  - Heptanoic Acids/*administration & dosage
MH  - Humans
MH  - Inflammation/blood/drug therapy
MH  - Interleukin-6/blood
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Pyrroles/*administration & dosage
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/analysis
MH  - Vascular Cell Adhesion Molecule-1/blood
EDAT- 2005/07/09 09:00
MHDA- 2006/09/28 09:00
CRDT- 2005/07/09 09:00
PHST- 2005/05/12 00:00 [received]
PHST- 2005/05/21 00:00 [revised]
PHST- 2005/05/21 00:00 [accepted]
PHST- 2005/07/09 09:00 [pubmed]
PHST- 2006/09/28 09:00 [medline]
PHST- 2005/07/09 09:00 [entrez]
AID - S0167-5273(05)00790-4 [pii]
AID - 10.1016/j.ijcard.2005.05.055 [doi]
PST - ppublish
SO  - Int J Cardiol. 2006 Apr 28;109(1):48-52. doi: 10.1016/j.ijcard.2005.05.055. Epub 
      2005 Jul 6.